TO THE EDITOR
Emerging preclinical and clinical data suggest that T cells recognize and kill malignant cells in patients with hematological malignant disorders. The lower rates of relapse in the setting of allogeneic transplantation compared with those in autologous bone marrow transplantation, the striking clinical benefit of donor-lymphocyte infusions as well as the finding that human T cells can destroy chemotherapy-resistant cell lines from chronic myeloid leukemia and multiple myeloma, have prompted development of immunotherapeutic strategies against hematological cancers.
1 Among these approaches, active specific immunization or vaccination is emerging as a valuable tool to boost the adaptive immune system against malignant cells. In this regard, the identification of leukemia-associated antigens is crucial. However, very few antigens are characterized in a conceptual framework in which the biology, microenvironment, and conventional disease management have been taken into consideration. The antiapoptotic protein Mcl-1 plays an important role in cancer as it has been directly linked to resistance to conventional forms of therapies and poor prognosis.
2 Accordingly, downregulation of Mcl-1 would severely inflict the survival capacity of tumor cells, which highlights this protein as a prime candidate as vaccination target in therapeutic vaccinations against cancer, since it is not subject to immune selection as well as it would synergistically boosts the effects of conventional cytotoxic therapies. Recently, we demonstrated that cancer patients of different origin host spontaneous T-cell responses specifically against Mcl-1-derived peptides presented in the context of the HLA-A3 antigen. 3 In the present study, the amino-acid sequence of the Mcl-1 protein was screened for the most probable HLA-A1 nona-and decamer peptide epitopes, using the main HLA-A1-specific anchor residues. 4 PBL from seven healthy individuals, five patients with CLL, six melanoma patients, and four patients with breast cancer were examined. All individuals were HLA-A1 positive. The average number of peptide-specific spots (after subtraction of spots without added peptide) was calculated for each patient using the ImmunoSpot peptides only bound HLA-A1 very weakly. Subsequently, we scrutinized PBL from HLA-A1 þ cancer patients of different origins by means of ELISPOT against the Mcl-1(177-185) peptide as described. 3 Indeed, strong and frequent CTL responses were detected against this peptide in cancer patients of different origins. We were able to detect a response against the Mcl-1(177-185) in HLA-A1 þ PBL in three out of five examined CLL patients (responders are defined as average number of antigen-specific cells 71/2 standard deviation 425 per 10 5 cells), two out of six examined melanoma patients, and three out of four examined breast cancer patients (Figure 1b) . Importantly, we were not able to detect a response in any of the seven HLA-A1 þ healthy individuals we examined as controls (Figure 1b) . The characterization of multiple Mcl-1 epitopes with different HLA class I restriction elements broadens the clinical potential of this target antigen in several important ways: Targeting different HLA molecules in a multiepitope vaccine will increase the number of patients eligible for immunotherapy and will further decrease the risk of immune escape by class I HLA-allele loss; loss of a single class I HLA allele is a significant component of MHC alterations described in cancer cells, whereas total loss of class I HLA expression is rare. 5 The attractiveness of using Mcl-1 for vaccination purposes relies on the fact that downregulation or loss of expression of this protein as a means of immune escape would impair sustained tumor growth. The availability of multiple Mcl-1 epitopes presented by different HLA class I restriction elements further reduces the risk of immune escape and thereby therapeutic failures. Finally, the immunodominance of a given peptide epitope differ among individual patients depending on several factors such as the T-cell receptor repertoire, which are almost impossible to predetermine. Thus, a variety of epitopes ensures that the respective immune-dominant epitope is actually used. Apoptosis was originally defined as a mode of cell death with specific morphology. 1 Since the discovery of caspase proteases, it has been evident that caspase activation was indispensable for apotosis to occur in various mammalian cell types. First reports in the early 1990s demonstrated that the broad-spectrum caspase inhibitors such as z-VAD-fmk could effectively block apoptosis in several animal cell death models.
2 Later on, it was rather surprisingly demonstrated that caspase inhibitors were unable to prevent cells from death; cells still died, although more slowly while exhibiting necrosis-like morphology. 3 Further research revealed that mitochondria play crucial role in both caspase-dependent and -independent commitment to cell death. Various extracellular and intracellular insults may eventually lead to the release of proteins that reside in intermembrane space of mitochondria resulting in cell death. Some of these proteins including cytochrome c and Smac/DIABLO act as caspase activators. The others, including AIF (apoptosis-inducing factor) and endonuclease G, contribute to caspase-independent cell death. Omi/HtrA2, a serine protease that also reside in intermembrane mitochondrial space, can act in both ways. 4 Recently, Okada and co-workers 5 observed that serine protease inhibitors TLCK and TPCK prevented the z-VAD-fmk plus imatinib-induced necrosis-like programmed cell death (PCD) pathway. They further found that serine protease inhibitors alone failed to prevent imatinib-treated cells from death. Interestingly, serine protease inhibitors even promoted cell death in imatinibtreated cells. 5 Authors concluded that imatinib mesylate induced a caspase-independent, necrosis-like PCD mediated by the serine protease activity of Omi/HtrA2. 5 Their experiments were mainly
